Teva Canada Ranitidine Product Recall (2019-10-17)

Teva Canada Ranitidine Product Recall (2019-10-17) - Recalls and safety alerts
Starting date:
October 17, 2019
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type I
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-71339

Last updated:

2019-10-18
  • Product: A.  ACT-Ranitidine 150 mg Tablet;    B.  ACT-Ranitidine 300 mg Tablet

A.  ACT-Ranitidine 150 mg Tablet;  

B.  ACT-Ranitidine 300 mg Tablet

Affected lots may be manufactured with an API containing an impurity, N-nitrosodimethylamine (NDMA).

Wholesalers, Healthcare Establishments, Retailers

 
DIN 02248570

Tablet

Ranitidine 150 mg

K51136, K58444, K50205, K50860, K51114, K51139, K51141, K52964, K58446, K46486, K50593, K51071, K51076, K51144, K51146, K51148, K51150, K51152, K51154, K51164, K52965, K52966, K55591, K50203, K51069, K51132

Recalling Firm
Teva Canada Limited 30 Novopharm Court Toronto M1B 2K9 Ontario CANADA

 

Marketing Authorization Holder
Teva Canada Limited 30 Novopharm Court Toronto M1B 2K9 Ontario CANADA

 

 

 
DIN 02248571

Tablet

Ranitidine 300 mg

K50175, K50944, K51170, K51171, K51172, K51173

Recalling Firm
Teva Canada Limited 30 Novopharm Court Toronto M1B 2K9 Ontario CANADA

 

Marketing Authorization Holder
Teva Canada Limited 30 Novopharm Court Toronto M1B 2K9 Ontario CANADA

 

 

To read more Press Release articles, click here.